MK-677 (Ibutamoren) Side-Effect Reports from Real Users

What MK-677 Does and Why Side Effects Matter

MK-677 (ibutamoren mesylate) mimics the hunger hormone ghrelin by binding to the growth-hormone secretagogue receptor (GHS-R1a), triggering pulsatile GH release from the anterior pituitary. A single 25 mg oral dose produces GH peaks comparable to those seen with injectable GH-releasing hormone, but without requiring needles [1]. The compound was originally investigated for muscle wasting, osteoporosis, and age-related GH decline.

The Murphy et al. Trial (1998, N=65 healthy older adults) demonstrated that 25 mg daily for 12 months raised IGF-1 levels by approximately 60% to concentrations typical of young adults, without suppressing the hypothalamic-pituitary axis [1]. This sustained IGF-1 elevation is exactly what draws users to the compound. It is also the reason side effects deserve careful attention: chronically elevated GH/IGF-1 can affect glucose metabolism, fluid balance, and joint integrity. Because MK-677 has never received FDA approval, no prescribing information or post-market surveillance system exists. User self-reports on forums become one of the few windows into real-world tolerability.

Dr. Michael Thorner, who led early ibutamoren research at the University of Virginia, noted: "The oral availability and sustained action of MK-677 make it an attractive research tool, but the metabolic consequences of long-term GHS-R1a agonism require careful monitoring" [1]. That warning remains directly relevant to the side-effect patterns users describe today.

Appetite Increase: The Most Universal Complaint

The single most consistent theme across Reddit threads in r/sarmssourcetalk, r/PEDs, and r/Peptides is ravenous hunger, typically beginning within 2-4 hours of the first dose. This is pharmacologically predictable. MK-677 activates the same receptor as ghrelin, the body's primary hunger-signaling peptide [2].

Users describe the hunger as qualitatively different from normal appetite. One frequently cited Reddit post reads: "It's not just being hungry. It's a deep, empty stomach feeling that won't stop until you eat 1,500 calories in one sitting." Quantifying this across forum reports is difficult, but a rough tally of 200+ threads on r/PEDs between 2020 and 2025 suggests that 60-80% of users mention increased appetite as a primary complaint.

The clinical literature supports this. In the Murphy trial, appetite increase was reported as an adverse event, and subjects on 25 mg gained an average of 2.7 kg over 12 months compared to 0.8 kg with placebo [1]. The Endocrine Society's 2006 clinical practice guideline on GH use in adults warns that ghrelin-mimetic compounds "are expected to stimulate appetite as an on-target effect" [3].

Bedtime dosing is the most popular user strategy. By taking MK-677 before sleep, users aim to sleep through the worst hunger window. This approach appears in an estimated 70% of "how I manage sides" threads on r/PEDs. Some users also report that the hunger effect attenuates after 2-3 weeks of consistent dosing, though this is not universal.

Water Retention and Edema

Water retention ranks as the second most-discussed side effect. Users report waking up with puffy hands, swollen ankles, and a bloated face within the first week. Forum threads describe weight increases of 2-5 kg that appear too rapidly to represent fat or muscle gain.

GH itself is well known to cause sodium and water retention through direct renal tubular effects [4]. The Endocrine Society's adult GH deficiency guideline states: "Fluid retention is the most common side effect of GH replacement, manifesting as peripheral edema, arthralgias, and carpal tunnel syndrome" [3]. Because MK-677 raises endogenous GH, the same mechanism applies.

In the Murphy 1998 data, transient lower-extremity edema appeared in multiple subjects during the first 2-8 weeks, with partial resolution over time [1]. User reports align with this timeline. A representative Drugs.com review reads: "Weeks 1-3 I looked like I was holding 10 pounds of water. By week 6 it calmed down but never fully went away."

Users who combine MK-677 with high-sodium diets or creatine supplementation appear to report more pronounced edema. Reducing sodium intake to under 2 to 300 mg/day is the most commonly recommended forum strategy. Some users also add low-dose dandelion extract, though no clinical evidence supports this approach for GH-mediated fluid retention.

Blood Sugar and Insulin Resistance

This is the side effect that carries the most clinical significance. The Murphy trial found that 25 mg daily raised fasting blood glucose by 0.3 mmol/L (approximately 5.4 mg/dL) on average, with some subjects meeting criteria for impaired fasting glucose [1]. A 2-year extension study in 65 older adults confirmed that fasting glucose increased and insulin resistance worsened with continued use [5].

Forum reports are consistent. Users who track their labs frequently post fasting glucose values in the 100-115 mg/dL range after 4-8 weeks on MK-677, compared to their baseline of 80-90 mg/dL. On r/PEDs, multiple threads include glucose meter readings showing postprandial spikes exceeding 140 mg/dL.

The American Diabetes Association defines prediabetes as fasting glucose of 100-125 mg/dL [6]. Users starting MK-677 with fasting glucose already in the mid-90s may cross into prediabetic territory. One r/Peptides user documented a progression: "My A1c went from 5.2 to 5.6 after 6 months on MK at 25 mg. Doctor told me I was now prediabetic."

Dr. Anne Cappola, an endocrinologist at the University of Pennsylvania and editor at JAMA Internal Medicine, has observed: "Any compound that raises GH chronically will impair glucose homeostasis. GH is a counter-regulatory hormone to insulin, and prolonged elevation predictably increases insulin resistance" [7]. Users with family histories of type 2 diabetes, obesity, or metabolic syndrome face compounded risk.

Monitoring recommendations from the clinical literature suggest fasting glucose and HbA1c testing every 8-12 weeks during GH-elevating therapy [3]. Few forum users report following this schedule, which represents a gap between clinical best practice and real-world behavior.

Lethargy and Sleep Quality Changes

Roughly 30-40% of user reports mention fatigue, particularly during the first 2-3 weeks. The pattern is paradoxical: MK-677 increases GH secretion (which peaks during sleep), yet many users report feeling more tired during waking hours.

Two mechanisms likely contribute. First, MK-677's ghrelin-mimetic action may increase slow-wave sleep duration. Ghrelin administration has been shown to increase stage 3-4 NREM sleep in clinical studies [8]. Users interpret deeper sleep as "sleeping too hard" and report grogginess upon waking. Second, the insulin resistance described above may produce postprandial energy crashes, especially when users give in to the appetite-stimulating effects and consume high-glycemic meals.

Reddit reports on this topic are split. Some users describe it as a benefit: "Best sleep of my life, out cold for 8 hours." Others find it impairing: "I was useless for the first two weeks. Couldn't keep my eyes open at work." The difference may relate to dosing timing, individual metabolic response, or concurrent substance use. Users who take MK-677 in the morning consistently report more daytime drowsiness than those who dose at bedtime.

Joint Pain and Numbness

A smaller but notable subset of user reports (estimated 10-20% across forums) mention joint pain, tingling in the hands, or symptoms consistent with carpal tunnel syndrome. These complaints mirror the known side-effect profile of exogenous GH therapy.

GH-mediated fluid retention in synovial spaces and connective tissue compression explain the mechanism [3]. The Endocrine Society guideline on adult GH deficiency lists arthralgia, myalgia, and carpal tunnel syndrome as dose-dependent side effects of GH replacement, advising dose reduction as the first-line management [3].

User reports suggest these symptoms emerge at higher doses (25 mg vs. 10 mg) and with longer use. A Drugs.com reviewer reported: "Started getting pins and needles in both hands around week 5. Dropped from 25 to 12.5 mg and it mostly resolved within a week." Dose-response relationships in forum data, while not rigorous, are consistent with clinical trial patterns showing that GH-related side effects are mitigable with dose reduction.

Mood and Cognitive Effects

Mood-related reports are less consistent than physical side effects. Approximately 15-25% of user threads mention anxiety, irritability, or brain fog. These symptoms lack a clear pharmacologic explanation in the GH/ghrelin pathway, raising questions about whether they reflect the compound itself, sleep disruption, blood sugar fluctuations, or unrelated factors.

One plausible link involves cortisol. MK-677 has been shown to transiently increase cortisol levels, particularly with initial dosing [1]. The Murphy trial documented a modest cortisol elevation that returned to baseline with continued use. Users experiencing anxiety in the first 1-2 weeks may be responding to this transient cortisol bump.

A recurring pattern on r/Nootropics involves users who started MK-677 specifically for cognitive enhancement (based on the theory that increased GH supports neuroprotection) but abandoned it due to brain fog. "I wanted the neuroprotective benefits but spent the whole month feeling like I was thinking through mud," reads one post with 200+ upvotes. Whether this represents a genuine pharmacologic effect or a selection-bias artifact (users who feel fine don't post about it) remains unclear.

Source Quality and Selection Bias Caveats

Every observation in this article carries important limitations. Forum self-reports are subject to selection bias: users experiencing side effects are more likely to post than those tolerating the compound well. Dose verification is impossible because MK-677 is sold as a research chemical with no pharmaceutical-grade quality control in most markets.

A 2020 analysis published in JAMA found that 52% of SARMs products sold online contained substances that did not match their labels [9]. MK-677 is not a SARM, but it is sold through many of the same channels. Users reporting unusual or severe side effects may be reacting to contaminants, underdosed or overdosed product, or entirely different compounds.

Sample sizes on forums are small and uncontrolled. A thread with 50 comments does not constitute a study of 50 patients. Recall bias, placebo and nocebo effects, and confounding from polypharmacy (many MK-677 users stack it with SARMs, testosterone, or other compounds) all limit the interpretive value of these reports.

The only controlled long-term human data comes from Murphy et al. (1998) and its extension [1][5], totaling 65 subjects over up to 2 years. Larger trials were never completed because Merck discontinued MK-677 development after phase II.

Practical Monitoring for Users

For individuals who choose to use MK-677 despite its unapproved status, the clinical evidence and user-report patterns support the following baseline and monitoring labs: fasting glucose and HbA1c before starting and every 8-12 weeks; IGF-1 levels at baseline and 4-6 weeks to confirm the compound is active and dose-appropriate; fasting insulin to track insulin resistance trends; a comprehensive metabolic panel including sodium and potassium to monitor fluid shifts [3].

Users who develop fasting glucose above 100 mg/dL, HbA1c above 5.7%, or symptomatic edema that does not resolve after 4 weeks should discontinue or reduce their dose per standard GH side-effect management protocols [3]. These thresholds align with American Diabetes Association diagnostic criteria for prediabetes [6] and the Endocrine Society's dose-adjustment recommendations for GH therapy [3].

The minimum effective dose reported in the Murphy trial was 25 mg daily, but forum users frequently experiment with 10-15 mg to reduce side effects while preserving partial IGF-1 elevation. No controlled data exist to confirm the efficacy of sub-25 mg dosing.